CBS promoter hypermethylation increases the risk of hypertension and stroke

Authors

  • Changyi Wang Jinan University, Integrated Chinese and Western Medicine Postdoctoral research station https://orcid.org/0000-0003-3153-9458
  • Guodong Xu Ningbo University, Department of Preventive Medicine, School of Medicine https://orcid.org/0000-0002-6464-6164
  • Qi Wen Shenzhen Nanshan Center for Chronic Disease Control, Department of Non-communicable Disease Prevention and Control
  • Xiaolin Peng Shenzhen Nanshan Center for Chronic Disease Control, Department of Non-communicable Disease Prevention and Control
  • Hongen Chen Shenzhen Nanshan Center for Chronic Disease Control, Department of Non-communicable Disease Prevention and Control
  • Jingwen Zhang Shenzhen Nanshan Center for Chronic Disease Control, Department of Non-communicable Disease Prevention and Control
  • Shan Xu Shenzhen Nanshan Center for Chronic Disease Control, Department of Non-communicable Disease Prevention and Control
  • Chunhui Zhang Shenzhen Nanshan Center for Chronic Disease Control, Department of Non-communicable Disease Prevention and Control
  • Min Zhang Shenzhen Nanshan Center for Chronic Disease Control, Department of Non-communicable Disease Prevention and Control
  • Jianping Ma Shenzhen Nanshan Center for Chronic Disease Control, Department of Non-communicable Disease Prevention and Control
  • Zhaohui Hui Shenzhen Xili People’s Hospital
  • Guifu Wu The Eighth Affiliated Hospital of Sun Yat-sen University, Department of Cardiology
  • Min Ma Institute of Integrated Traditional Chinese and Western Medicine of Jinan University https://orcid.org/0000-0003-3111-509X

DOI:

https://doi.org/10.6061/clinics/2019/e630

Keywords:

CBS, Hypermethylation, Hypertension, Stroke, Homocysteine

Abstract

OBJECTIVES: Cystathionine β-synthase is a major enzyme in the metabolism of plasma homocysteine. Hyperhomocysteinemia is positively associated with hypertension and stroke. The present study was performed to examine the possible effects of Cystathionine β-synthase promoter methylation on the development of hypertension and stroke. METHODS: Using quantitative methylation-specific PCR, we determined the Cystathionine β-synthase methylation levels in 218 healthy individuals and 132 and 243 age- and gender-matched stroke and hypertensive patients, respectively. The relative changes in Cystathionine β-synthase promoter methylation were analyzed using the 2- ΔΔCt method. The percent of the methylated reference of Cystathionine β-synthase was used to represent the Cystathionine β-synthase promoter methylation levels. RESULTS: In this study, the Cystathionine β-synthase promoter methylation levels of hypertensive and stroke participants were both higher than that of the healthy individuals (median percentages of the methylated reference were 50.61%, 38.05% and 30.53%, respectively, all p<0.001). Multivariable analysis showed that Cystathionine β-synthase promoter hypermethylation increased the risk of hypertension [odds ratio, OR (95% confidence interval, CI)=1.035 (1.025–1.045)] and stroke [OR (95% CI)=1.015 (1.003–1.028)]. The area under the curve of Cystathionine β-synthase promoter methylation was 0.844 (95% CI: 0.796–0.892) in male patients with hypertension and 0.722 (95% CI: 0.653–0.799) in male patients with stroke. CONCLUSION: Cystathionine β-synthase promoter hypermethylation increases the risk of hypertension and stroke, especially in male patients.

Downloads

Download data is not yet available.

Downloads

Published

2019-05-10

Issue

Section

Original Articles

How to Cite

CBS promoter hypermethylation increases the risk of hypertension and stroke. (2019). Clinics, 74, e630. https://doi.org/10.6061/clinics/2019/e630